TGFB1 and liver disorder: Although inhibiting TGF-β may be considered a therapeutic tool in liver diseases [167,168], the discovery of NOXs as TGF-β targets mediating its detrimental effects in liver inflammation and fibrosis pushed to the challenge of using NOX inhibitors as a more specific and adequate way to attack fibrotic pathologies [169].